RECRUITING

Biological Effects of Quercetin in COPD

Conditions

Chronic Obstructive Pulmonary Disease Inflammation Oxidative stress Plant polyphenol Flavonols

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receive quercetin 2000 mg/day and 4 subjects receive placebo.

Official Title

Impact of Quercetin on Inflammatory and Oxidative Stress Markers in COPD

Quick Facts

Study Start:2019-10-01

Study Completion:2025-07-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03989271

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Subjects with COPD, 40 - 80 yrs of age * Post-bronchodilator forced expiratory volume (FEV)1/forced vital capacity (FVC) ratio 0.7, FEV1% predicted between 40 to 70 * Both active and ex-smokers with at least 10 pack-years history of smoking * COPD patients taking H2 antagonists, loperamide or loratadine and willing to stop during the study period	* Known allergy/sensitivity to quercetin * Subjects with primary current diagnosis of asthma * Upper respiratory tract infection within two weeks of the screening visit * Acute bacterial infection requiring antibiotics within two weeks of screening * Emergency treatment or hospitalization within one month of screening for any reasons * Unwillingness to stop flavonoid supplementation * Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener * Daily warfarin or cyclosporine (Neoral, Sandimmune) * Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period * Lung cancer history or undergoing chemo- or radiation therapy * Inflammatory bowel disease * Subjects with no detectable levels of inflammatory CRP or SP-D in blood and/or IL- * Women of child-bearing age and unwilling to take pregnancy test * Child-bearing age, who are unwilling to use adequate contraception or abstain during the course of the study. * Pregnant or lactating mothers

Inclusion Criteria

Exclusion Criteria

* Subjects with COPD, 40 - 80 yrs of age
* Post-bronchodilator forced expiratory volume (FEV)1/forced vital capacity (FVC) ratio 0.7, FEV1% predicted between 40 to 70
* Both active and ex-smokers with at least 10 pack-years history of smoking
* COPD patients taking H2 antagonists, loperamide or loratadine and willing to stop during the study period

* Known allergy/sensitivity to quercetin
* Subjects with primary current diagnosis of asthma
* Upper respiratory tract infection within two weeks of the screening visit
* Acute bacterial infection requiring antibiotics within two weeks of screening
* Emergency treatment or hospitalization within one month of screening for any reasons
* Unwillingness to stop flavonoid supplementation
* Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener
* Daily warfarin or cyclosporine (Neoral, Sandimmune)
* Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period
* Lung cancer history or undergoing chemo- or radiation therapy
* Inflammatory bowel disease
* Subjects with no detectable levels of inflammatory CRP or SP-D in blood and/or IL-
* Women of child-bearing age and unwilling to take pregnancy test
* Child-bearing age, who are unwilling to use adequate contraception or abstain during the course of the study.
* Pregnant or lactating mothers

Contacts and Locations

Study Contact

Umadevi Sajjan, Ph.D

CONTACT

2157077139

Uma.Sajjan@temple.edu

Principal Investigator

Nathaniel Marchetti, D.O.

PRINCIPAL_INVESTIGATOR

Temple University

Study Locations (Sites)

Nathaniel Marchetti

Philadelphia, Pennsylvania, 19140

United States

Collaborators and Investigators

Sponsor: Temple University

Nathaniel Marchetti, D.O., PRINCIPAL_INVESTIGATOR, Temple University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-10-01

Study Completion Date2025-07-01

Study Record Updates

Study Start Date2019-10-01

Study Completion Date2025-07-01

Terms related to this study

Keywords Provided by Researchers

Inflammation
Oxidative stress
Plant polyphenol
Flavonols

Additional Relevant MeSH Terms

Chronic Obstructive Pulmonary Disease